

**Annual reporting of the collaboration between WHO and Worldwide Network for Blood and Marrow Transplantation (WBMT)
for the period 2022-2024 in the context of Official Relations**

The WHO Executive Board admitted Worldwide Network for Blood and Marrow Transplantation (WBMT) into official relations with WHO. The official relations are governed by the Framework of Engagement with non-State actors, according to which the basis of official relations is a plan for collaboration between WHO and the non-State actor with agreed objectives and outlining activities for a three-year period, structured in accordance with the General Programme of Work and Programme Budget and consistent with the Framework. These plans are expected to be free from concerns which are primarily of a commercial or profit-making nature.

According to paragraph 52 of the Framework, the organizations in official relations with WHO “shall provide annually a short report on the progress made in implementing the plan of collaboration and other related activities which will also be published in the WHO register¹.”

As participation in WHO meetings is not considered to be a joint activity in the context of official relations, it is not included in this report.

¹ Link to WHO Register of non-State actors: <https://publicspace.who.int/sites/GEM/default.aspx>

1. Area of collaboration ²				
WHO Strategic Priority: Strategic Priority 1: One billion more people benefiting from universal health coverage				
WHO Outcome: Outcome 1.1 - improved access to quality essential health services Outcome 1.3 - improved access to essential medicines, vaccines, diagnostics and devices for primary health care				
Description of the activities, expected deliverables and timeframe as reflected in the agreed plan for collaboration between WHO and the entity. For each agreed activity in the plan for collaboration, please indicate the implementation progress made for year 1, 2 and 3, as well as any comments to support the progress rating.				
Activities	Expected Deliverable	Year 1 - 2022	Year 2 - 2023	Year 3 – 2024
1. Provide technical input and relevant data that may inform WHO's work on raising awareness and addressing the burden of diseases/conditions that are amenable to HCT.	a) Report containing a review of diseases and conditions that can be treated by HCT, addressing the prevalence (burden) and regional/country perspectives and estimates on how many patients can be saved is submitted for WHO's consideration; b) Report on global diffusion of HCT with specific focus on country capacities, number of transplant centres, health workforce, donor registries, unmet needs, etc. is submitted for WHO's consideration.	Implementation progress rating: <input type="checkbox"/> Completed <input checked="" type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined	Implementation progress rating: <input type="checkbox"/> Completed <input type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined Comments for declined activities only, if necessary and relevant to the implementation progress (max 100 words)	Implementation progress rating: <input type="checkbox"/> Completed <input type="checkbox"/> Partially implemented <input type="checkbox"/> Declined Please provide justification for activities partially implemented or declined.

² Please refrain from changing text in the fields related to: WHO strategic priority, WHO outcome, activities and expected deliverable, since these were agreed upon and approved by the Executive Board as included in the collaboration plan, and cannot be modified. Implementation progress for years already reported in this form cannot be modified either. Additional information on the WHO Strategic Priority and WHO Outcomes are provided in the following source: <https://apps.who.int/iris/bitstream/handle/10665/341371/9789240012776-eng.pdf?sequence=1&isAllowed=y>

<p>2. Provide technical input that may inform WHO's work towards developing guidance materials for establishing Hematopoietic Stem Cell Transplantation programmes at country-level.</p>	<p>a) Report containing best practices identified and proposals on the criteria for minimum requirements and existing standards for HCT, including costing and essential medications is submitted for WHO's consideration; b) Report containing a review of current donor options worldwide, ethical challenges identified for minors as donors, and existing standards for selection (related and unrelated), quality and safety, is submitted for WHO's consideration.</p>	<p>Implementation progress rating:</p> <input type="checkbox"/> Completed <input checked="" type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined	<p>Implementation progress rating:</p> <input type="checkbox"/> Completed <input type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined <p>Comments for declined activities only, if necessary and relevant to the implementation progress (max 100 words)</p>	<p>Implementation progress rating:</p> <input type="checkbox"/> Completed <input type="checkbox"/> Partially implemented <input type="checkbox"/> Declined <p>Please provide justification for activities partially implemented or declined.</p>
<p>3. Under WHO's guidance, support WHO's work towards the development of knowledge resources to build capacity in low and low-middle income countries selected by WHO and in agreement with national authorities for starting or strengthening HCT programs, in line with WHO's guiding principles.</p>	<p>Develop a toolkit, including: assessment tools for benchmarking of care, training modules for webinars, online resources (slides, videos) and adaptation tools for setting up HCT in low-resource settings. This includes visual material for outlining essential elements for a successful HCT unit and system components for sustainability and low-cost practices. Content and materials will be reviewed and validated by WHO. The tools will be disseminated through agreed communications channels and in line with WHO's rules and policies.</p>	<p>Implementation progress rating:</p> <input type="checkbox"/> Completed <input checked="" type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined	<p>Implementation progress rating:</p> <input type="checkbox"/> Completed <input type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined <p>Comments for declined activities only, if necessary and relevant to the implementation progress (max 100 words)</p>	<p>Implementation progress rating:</p> <input type="checkbox"/> Completed <input type="checkbox"/> Partially implemented <input type="checkbox"/> Declined <p>Please provide justification for activities partially implemented or declined.</p>

2. Area of collaboration

WHO Strategic Priority:

Strategic Priority 1: One billion more people benefiting from universal health coverage

Strategic Priority 3: One billion more people enjoying better health and well-being

WHO Outcome:

Outcome 1.1 - improved access to quality essential health services

Outcome 1.3 - improved access to essential medicines, vaccines, diagnostics and devices for primary health care

Outcome 3.2 - risk factors reduced through multisectoral action

Description of the activities, expected deliverables and timeframe as reflected in the agreed plan for collaboration between WHO and the entity. For each agreed activity in the plan for collaboration, please indicate the implementation progress made for year 1, 2 and 3, as well as any comments to support the progress rating.

Activities	Expected Deliverable	Year 1 - 2022	Year 2 - 2023	Year 3 – 2024
1. Provide technical input that may inform WHO in assessing access to cell and gene therapies worldwide in line with current WHO frameworks and guidelines.	Proposal - outline for a worldwide survey on current use of cell and gene therapies and future needs, including mapping of how practices are regulated, is submitted for WHO's consideration.	Implementation progress rating: <input type="checkbox"/> Completed <input checked="" type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined	Implementation progress rating: <input type="checkbox"/> Completed <input type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined Comments for declined activities only, if necessary and relevant to the implementation progress (max 100 words)	Implementation progress rating: <input type="checkbox"/> Completed <input type="checkbox"/> Partially implemented <input type="checkbox"/> Declined Please provide justification for activities partially implemented or declined.
2. Provide technical input that may inform WHO's work in the development of resources and tools for strengthening the oversight capacity at global and national level, in line with WHO's principles.	Proposal for a tool on how to monitor practices worldwide is submitted for WHO's consideration.	Implementation progress rating: <input type="checkbox"/> Completed <input type="checkbox"/> On-going <input checked="" type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined	Implementation progress rating: <input type="checkbox"/> Completed <input type="checkbox"/> On-going <input type="checkbox"/> Pending/Yet to be started <input type="checkbox"/> Declined Comments for declined activities only, if necessary and relevant to the implementation progress (max 100 words)	Implementation progress rating: <input type="checkbox"/> Completed <input type="checkbox"/> Partially implemented <input type="checkbox"/> Declined Please provide justification for activities partially implemented or declined.

<p>3. Provide technical input that may inform WHO's work on development of quality and safety guidance for gene and cell therapies, in line with the relevant WHO regulatory frameworks and guidelines.</p>	<p>Report containing a review of current safety standards, quality management systems and accreditation processes currently available for the development of gene and cell therapies, is submitted for WHO's consideration.</p>	<p>Implementation progress rating:</p> <p><input checked="" type="checkbox"/> Completed</p> <p><input type="checkbox"/> On-going</p> <p><input type="checkbox"/> Pending/Yet to be started</p> <p><input type="checkbox"/> Declined</p>	<p>Implementation progress rating:</p> <p><input type="checkbox"/> Completed</p> <p><input type="checkbox"/> On-going</p> <p><input type="checkbox"/> Pending/Yet to be started</p> <p><input type="checkbox"/> Declined</p> <p>Comments for declined activities only, if necessary and relevant to the implementation progress (max 100 words)</p>	<p>Implementation progress rating:</p> <p><input type="checkbox"/> Completed</p> <p><input type="checkbox"/> Partially implemented</p> <p><input type="checkbox"/> Declined</p> <p>Please provide justification for activities partially implemented or declined.</p>
---	---	--	---	---